Home > Cardiology > ACC 2021 > Interventional and Structural Cardiology > Men and women benefit equally from early aspirin withdrawal following PCI

Men and women benefit equally from early aspirin withdrawal following PCI

Presented By
Dr Birgit Vogel, Icahn School of Medicine, USA
Conference
ACC 2021
Trial
TWILIGHT
A recent subgroup analysis of the TWILIGHT trial showed that while post-percutaneous coronary intervention (PCI) bleeding occurs more frequently in women; this is mostly attributable to baseline differences. Recurrent ischaemic events were similar between the sexes [1]. The TWILIGHT study (NCT02270242) was a double-blind, placebo-controlled study comparing the use of ticagrelor plus aspirin with the use of ticagrelor plus placebo (ticagrelor monotherapy) for 1 year in high-risk patients who had undergone PCI and had already completed 3 months of dual antiplatelet therapy. TWILIGHT demonstrated that ticagrelor monotherapy reduced the risk of bleeding compared with dual antiplatelet therapy. Dr Birgit Vogel (Icahn School of Medicine, NY, USA) presented a pre-specified analysis that explored heterogeneity of outcomes...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on